Sebastian Lange

Title: Sebastian Lange: Innovator in Oncolytic Virus Research

Introduction

Sebastian Lange is a notable inventor based in Tuebingen, Germany. He has made significant contributions to the field of pharmaceutical compositions, particularly in the development of oncolytic viruses for cancer treatment. With a total of 2 patents, Lange's work is paving the way for innovative therapies in oncology.

Latest Patents

Lange's latest patents focus on the oncolytic measles virus. The first patent pertains to a pharmaceutical composition that includes a recombinant measles virus encoding a suicide gene. This composition is designed for the treatment of malignant cells that exhibit primary or secondary resistance against an oncolytic measles virus without suicide gene activity. Additionally, the invention includes a recombinant measles virus based on the measles vaccine strain Schwarz, which encodes a suicide gene. This virus comprises a fusion of cytosine deaminase, particularly yeast cytosine deaminase, and uracil phosphoribosyltransferase, particularly yeast uracil phosphoribosyltransferase. The patent also details a method and a kit for preparing the recombinant measles virus as claimed.

Career Highlights

Throughout his career, Sebastian Lange has focused on innovative approaches to cancer treatment. His research has led to advancements in the use of viral therapies, which hold promise for patients with resistant forms of cancer. His dedication to this field has established him as a key figure in oncolytic virus research.

Collaborations

Lange has collaborated with notable colleagues, including Ulrich Manfred Lauer and Michael Bitzer. These partnerships have contributed to the development and refinement of his innovative research.

Conclusion

Sebastian Lange's work in the field of oncolytic viruses represents a significant advancement in cancer treatment. His innovative patents and collaborations highlight his commitment to improving therapeutic options for patients.